Lissette Libby, NP
Family · Hollywood, MDNPI 1356910244
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 366 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,178 and has fallen 84.1% since, to $505 in 2025. Among family clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 366 payments — averaging $23.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Amgen$769
- United Therapeutics Corporation$480
- Mallinckrodt Hospital Products Inc.$468
- Boehringer Ingelheim$440
- plus $3K from 33 others
What the payments were for
- Food & beverage$8,16196%
- Education$3644%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 55 | $1,777 |
| GSK | 59 | $1,214 |
| Amgen | 23 | $769 |
| United Therapeutics Corporation | 24 | $480 |
| Mallinckrodt Hospital Products Inc. | 18 | $468 |
| Boehringer Ingelheim | 23 | $440 |
| Paratek Pharmaceuticals, Inc. | 21 | $403 |
| Actelion Pharmaceuticals US, Inc. | 13 | $386 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $328 |
| ANI Pharmaceuticals, Inc. | 11 | $278 |
| Regeneron Healthcare Solutions, Inc. | 9 | $270 |
| Sanofi | 10 | $232 |
| AbbVie | 15 | $190 |
| Mylan Specialty L.p. | 16 | $170 |
| Grifols USA, LLC | 6 | $136 |
| Merck | 5 | $130 |
| Pfizer | 4 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Philips North America LLC | 5 | $75 |
| Bayer | 3 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Pharming Healthcare, Inc. | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $48 |
| Inogen, Inc. | 2 | $43 |
| Baxter Healthcare | 2 | $36 |
| Electromed, Inc. | 2 | $33 |
| Nabriva Therapeutics, PLC | 2 | $29 |
| Novartis | 1 | $28 |
| Genentech USA, Inc. | 1 | $24 |
| Insmed, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| UCB, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $14 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,524 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $141,896 |
| Spiriva RespimatTiotropium Bromide | 49 | $63,968 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $56,830 |
| Advair HfaFluticasone Propion/Salmeterol | 31 | $23,270 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $20,309 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $20,265 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $13,404 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $11,943 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 211 | $6,380 |
| Ventolin HfaAlbuterol Sulfate | 35 | $4,014 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $3,610 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,000 |
| Montelukast Sodium | 91 | $1,072 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $929 |
| Ipratropium Bromide | 20 | $744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,214 | $175,565162 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $440 | $84,27773 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,777 | $68,77382 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.
Other family in Hollywood
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Ariana ChaoLutherville$85K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.